WeVote
Log In

Bill

Bill

SB 256

establishing safety and care requirements for clinician-administered drugs.

2026 Regular Session Introduced by Bill Gannon and 3 co-sponsors

SB 256 establishes safety and care standards for clinician-administered medications in New Hampshire to standardize protocols and oversight across healthcare settings.

Refer for Interim Study: MA VV 05/14/2026 HJ 13
0
WeVote Research Nonpartisan
Bill Summary · SB 256

Legislative bill overview

SB 256 establishes new safety and care requirements for drugs administered directly by clinicians in New Hampshire. The bill appears designed to standardize protocols and oversight for this category of medical administration. The legislative history shows it has undergone committee amendments and multiple referrals across health and commerce committees.

Why is this important

Clinician-administered drugs represent a significant portion of healthcare delivery, and standardized safety requirements can affect patient outcomes, healthcare provider compliance, and operational costs. Clear regulatory frameworks help prevent medication errors, ensure proper training, and establish accountability mechanisms across healthcare facilities.

Potential points of contention

  • Scope and definition clarity: Without seeing the full bill text, there may be disagreement over which drugs and which clinicians fall under these requirements, potentially creating compliance confusion
  • Implementation burden: Healthcare providers may argue new requirements increase administrative costs and staffing demands, while patient advocates may push for more stringent protections
  • Regulatory authority: Questions likely exist about whether these requirements should be enforced by the Department of Health and Human Services versus other agencies, and what penalties apply for non-compliance

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.